Michael Grunebaum

Associate Professor of Psychiatry at CUMC · New York Presbyterian Hospital

Credentials: · ·

History

IM Ketamine for Rapid Reduction of Suicidal Thoughts in High-Risk Emergency Room Patients: A Midazolam-Controlled Trial
National Institute of Mental Health · R01
Contact PI · $1.8M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2020–2028
Ketamine vs Midazolam: Testing Rapid Relief of Suicide Risk in Depression
National Institute of Mental Health · R01
Contact PI · $2.8M · New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, Inc
2012–2018
Paroxetine/Bupropion in Suicide Attempters/Ideators with Major Depression
National Institute of Mental Health · K23
Contact PI · $884.1K · Columbia University Health Sciences
2006–2012

IM Ketamine vs Midazolam for Suicidal ER Patients
Principal investigator · Suspended · Phase 4
New York State Psychiatric Institute
2021–2028
The Role of HNKs in the Antidepressant Effect of Ketamine
Principal investigator · Terminated · Phase 1
Columbia University
2019–2020
Ketamine for Suicidality in Bipolar Depression
Principal investigator · Completed · Phase 1, Phase 2
New York State Psychiatric Institute
2013–2018
Ketamine in the Treatment of Suicidal Depression
Principal investigator · Completed · Phase 4
New York State Psychiatric Institute
2012–2017